7 news items
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
VIR
5 Jun 24
for chronic hepatitis
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
VIR
5 Jun 24
antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
the Phase 2 SOLSTICE chronic hepatitis delta trial
Vir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
VIR
21 May 24
on participants that have reached 12 and 24 weeks of chronic suppressive treatment. The Company will also share 48-week treatment data on the efficacy
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
. The update will include data on participants that have reached 12 and 24 weeks of chronic suppressive treatment. The Company will also share 48-week
8u1a0t
VIR
13 May 24
of a treatment regimen for people living with chronic HBV infection and chronic hepatitis D virus (HDV) infection. The Breakthrough Therapy
w5wt6454rncdluqgjeiu34 zx9t2q
ANTX
VBIV
VIR
22 Mar 24
trigger a potent and specific immune response in chronic Hepatitis B (CHB) patients and linking that response to improved clinical outcomes
- Prev
- 1
- Next